Children's Hospital of Michigan is revolutionizing the treatment of beta thalassemia and sickle cell disease with groundbreaking gene therapy This innovative approach involves adding or modifying genes in the patient's bone marrow stem cells, minimizing the need for lifelong interventions. Eligible patients can now undergo potentially curative treatment at the hospital, known for its expertise in stem cell transplantation and gene therapy. This milestone reflects the hospital's commitment to exceptional care and fulfills the vision of the physician who first described beta thalassemia, Dr. Thomas Cooley, at the Children's Hospital of Michigan in the early 20th century. Gene therapy offers hope particularly for patients of African, Mediterranean, South Asian, and Middle Eastern descent disproportionately affected by these genetic conditions.
Click here to learn more about this life-altering treatment.
Click the button below to see an alphabetical listing of our faculty, where you can learn more about each physician's specialty, education, publications, and more.
UP is committed to advancing child health through research, scholarship and advocacy under the Central Michigan University College of Medicine/University Pediatrics Clinical Research Institute (CRI). CRI is the nexus for clinical and preclinical research at the Children’s Hospital of Michigan.
Click the button below to learn more about CRI, and view the CMU Discipline of Pediatrics annual progress report for information on our faculty's latest grants, publications, awards, and more.